 | Up a level |
Fischer, M., Wulff, B., Baruchel, S., Berlanga, P., Trahair, T., Mechinaud, F., Schulte, J., Modak, S., Merks, J. H., Zwaan, C. M., Marshall, L. V., Casanova, M., Branle, F., Malet, I., Emeremni, A. C. and Geoerger, B. (2016). Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population. Eur. J. Cancer, 69. S. S49 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Wolf, J., Schneider, C-P, Potzner, M., Arratia, Cazorla P., Shen, J., Branle, F. and von Pawel, J. (2015). The phase II ASCEND-7 (CLDK378A2205) trial: Ceritinib in patients (pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) metastatic to the brain and/or leptomeninges. Oncol. Res. Treat., 38. S. 138 - 139. BASEL: KARGER. ISSN 2296-5262